论文部分内容阅读
目的:比较孟鲁斯特钠与布地奈德对变应性鼻炎和鼻窦炎伴轻度支气管哮喘患者的临床疗效。方法:选取2014年7月—2015年7月间收治的变应性鼻炎和鼻窦炎伴轻度支气管哮喘患者80例,将其随机分为对照组和观察组(每组40例);对照组患者均给予布地奈德气雾剂吸入治疗,观察组患者均给予孟鲁斯特钠片口服治疗,比较两组患者治疗后的总有效率和血清ECP(嗜酸性细胞阳离子蛋白)值改善情况。结果:治疗后,观察组患者的总有效率为92.50%,明显高于对照组为82.50%(P<0.05);血清ECP值为(13.2±3.2)μg/L,显著低于对照组(17.3±3.8)μg/L(P<0.05)。结论:采用孟鲁斯特钠治疗变应性鼻炎和鼻窦炎伴轻度持续支气管哮喘患者的临床疗效优于布地奈德,前者可显著改善了患者血清ECP值,变应性鼻炎和鼻窦炎伴轻度支气管哮喘症状显著得以改善。
OBJECTIVE: To compare the clinical efficacy of montelukast sodium and budesonide in patients with allergic rhinitis and sinusitis with mild bronchial asthma. Methods: Eighty patients with allergic rhinitis and sinusitis with mild bronchial asthma who were admitted between July 2014 and July 2015 were randomly divided into control group and observation group (40 cases in each group). The control group Patients were given budesonide aerosol inhalation therapy, patients in the observation group were treated with montelukast sodium tablets oral treatment, the total effective rate and serum ECP (eosinophil cationic protein) value of two groups were compared. Results: After treatment, the total effective rate of the observation group was 92.50%, which was significantly higher than that of the control group (82.50%, P <0.05), and the serum ECP was (13.2 ± 3.2) μg / L, which was significantly lower than that of the control group ± 3.8) μg / L (P <0.05). CONCLUSIONS: The clinical efficacy of sodium montelukast in the treatment of patients with allergic rhinitis and sinusitis with mild persistent bronchial asthma is superior to budesonide, and the former can significantly improve the serum ECP, allergic rhinitis and sinusitis Mild bronchial asthma symptoms were significantly improved.